USPTO Examiner TSAY MARSHA M - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19173657EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEApril 2025August 2025Allow510YesNo
19173652EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEApril 2025December 2025Allow820YesNo
18901009BONE GELATIN PROCESSSeptember 2024June 2025Allow820NoNo
18889088COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSSeptember 2024May 2025Allow820NoNo
18755691Fusion protein and its preparation method for intermediate polypeptide of SemaglutideJune 2024November 2024Allow510YesNo
18737619MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSESJune 2024November 2025Abandon1710NoNo
18406031OLFACTORY RECEPTOR INVOLVED IN THE PERCEPTION OF MUSK FRAGRANCE AND THE USE THEREOFMay 2024July 2025Allow1910YesNo
18662446Enzyme Variants With Improved Ester Synthase PropertiesMay 2024April 2025Allow1110YesNo
18709446ENGINEERED SPLIT DHFR-BASED METHODS AND SYSTEMS FOR SELECTING CELLS THAT HAVE STABLY ACQUIRED A HETEROLOGOUS POLYNUCLEOTIDEMay 2024February 2026Abandon2111NoNo
18615341BOTULINUM NEUROTOXIN BIOHYBRIDMarch 2024June 2025Abandon1501NoNo
18584363PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEFebruary 2024March 2025Allow1310NoNo
18441456Cell-Free Protein SynthesisFebruary 2024January 2026Allow2320YesNo
18512485PROMOTER FOR YEASTNovember 2023September 2025Allow2220YesNo
18504590MUTANT LYSENIN PORESNovember 2023November 2024Allow1210YesNo
18503341NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOFNovember 2023February 2025Abandon1510NoNo
18502473TOXIN-DERIVED DELIVERY CONSTRUCTSNovember 2023February 2025Abandon1610NoNo
18384018SINGLE ALPHA CHAIN COLLAGENSOctober 2023November 2025Allow2521YesNo
18486403COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIESOctober 2023January 2025Abandon1510NoNo
18470985BIOMARKER ASSAY FOR USE IN MONITORING AUTISMSeptember 2023February 2025Allow1710NoNo
18461658EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORESeptember 2023October 2024Abandon1310NoNo
18231880METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTSAugust 2023December 2024Abandon1601NoNo
18351241EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEJuly 2023March 2025Abandon2020NoNo
18212427MODIFIED TRANSGLUTAMINASEJune 2023January 2026Allow3141YesNo
18310317COORDINATED COEXPRESSION OF THROMBINMay 2023October 2024Abandon1810NoNo
18123157ENGINEERED TISSUES HAVING STRUCTURAL COMPONENTS EMBEDDED THEREIN, AND METHODS OF MAKING AND USINGMarch 2023April 2025Abandon2520NoNo
18115724MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE AND METHOD FOR ENDOTOXIN-FREE PROTEIN PURIFICATIONFebruary 2023September 2024Abandon1910NoNo
18115585USING BIOSOURCED RAWS FROM WASTE STREAMS TO MAKE SOURCE MATERIALS FOR OILFIELD CHEMICAL MANUFACTUREFebruary 2023May 2025Abandon2740YesNo
18159281Methods And Devices For Detection Of Anticoagulants In Plasma And Whole BloodJanuary 2023June 2025Abandon2910NoNo
18159283Methods And Devices For Detection Of Anticoagulants In Plasma And Whole BloodJanuary 2023May 2025Abandon2810NoNo
18159276Methods And Devices For Detection Of Anticoagulants In Plasma And Whole BloodJanuary 2023April 2025Abandon2610NoNo
18158680MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING ADIPATE, 6-AMINOCAPROATE, HEXAMETHYLENEDIAMINE OR CAPROLACTAM RELATED THERETOJanuary 2023September 2024Abandon2001NoNo
18062234RATIONALLY-DESIGNED SYNTHETIC PEPTIDE SHUTTLE AGENTS FOR DELIVERING POLYPEPTIDE CARGOS FROM AN EXTRACELLULAR SPACE TO THE CYTOSOL AND/OR NUCLEUS OF A TARGET EUKARYOTIC CELL, USES THEREOF, METHODS AND KITS RELATING TO SAMEDecember 2022January 2025Allow2510NoNo
18056424OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USENovember 2022October 2024Allow2330NoNo
17925385FORMULATION OF PURE DIMETHOXY CURCUMIN-HUMAN SERUM ALBUMIN AND A PROCESS FOR THE PREPARATION THEREOFNovember 2022January 2026Abandon3810NoNo
18053577SHORT-ACTING FACTOR VII POLYPEPTIDESNovember 2022June 2024Abandon1911NoNo
17923180IMMUNOTHROMBOSIS IN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROMENovember 2022March 2026Abandon4010NoNo
17974381METHOD FOR PRODUCING NICOTINAMIDE MONONUCLEOTIDEOctober 2022January 2024Allow1520YesNo
17970051METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODSOctober 2022September 2024Abandon2311NoNo
18046371METHOD FOR POLISHING ALBUMINOctober 2022November 2023Abandon1301NoNo
17962153COMPOSITIONS, METHODS, AND APPLICATIONS OF A SYNTHETIC SURFACTANTOctober 2022March 2026Abandon4110NoNo
17894593Methods for Extracting Proteins from a Blood-Based MaterialAugust 2022September 2024Abandon2460NoNo
17890416STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERSAugust 2022December 2023Abandon1510NoNo
17760165MULTIPARTITE AND CIRCULARLY PERMUTED BETA-BARREL POLYPEPTIDES AND METHODS FOR THEIR USEAugust 2022March 2026Abandon4301NoNo
17814579PHARMACEUTICAL COMPOSITION FOR DIAGNOSING, PREVENTING OR TREATING LIVER CANCER USING SSU72 PROTEIN OR A POLYNUCLEOTIDE ENCODING THE SAMEJuly 2022November 2023Allow1621YesNo
17868077TOXIN-DERIVED DELIVERY CONSTRUCTSJuly 2022December 2023Abandon1710NoNo
17758825CELL-DERIVED VESICLES COMPRISING TARGET PROTEIN AND METHOD FOR PRODUCING SAMEJuly 2022November 2025Abandon4010NoNo
17861036ALCOHOL DEHYDROGENASE VARIANTSJuly 2022April 2024Abandon2111NoNo
17854334CLOSTRIDIAL TOXIN - HYALURONIC ACID COMPOSITIONSJune 2022November 2023Abandon1710NoNo
17790406Strain of Beijerinckia Fluminensis and Application Thereof in Arsenic OxidationJune 2022November 2025Abandon4110NoNo
17808450COMPOSITIONS AND METHODS FOR IDENTIFICATION OF MODULATORS OF RAS PROTEIN COMPLEXESJune 2022February 2026Abandon4410NoNo
17829032MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAMEMay 2022January 2026Abandon4320NoNo
17781266MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAMEMay 2022November 2025Abandon4120NoNo
17738484PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEMay 2022October 2023Allow1710YesNo
17771333LOW VOLUME TRANSFECTIONApril 2022September 2025Abandon4110NoNo
17722893Process for Isolating a High Purity Protein Preparation from Plant Material and Products ThereofApril 2022October 2024Abandon3090YesNo
17718116USE OF CATION-EXCHANGE CHROMATOGRAPHY IN THE FLOW-THROUGH MODE TO ENRICH POST-TRANSLATIONAL MODIFICATIONSApril 2022February 2024Allow2220YesNo
17577684PROCOAGULANT COMPOUNDSJanuary 2022November 2023Abandon2201NoNo
17563665System and Method for Improved Transient Protein Expression in CHO CellsDecember 2021January 2025Abandon3630NoNo
17548410HYBRID SUGAR TRANSPORTERS WITH ALTERED SUGAR TRANSPORT ACTIVITY AND USES THEREOFDecember 2021May 2024Allow2921YesNo
17548124RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAMEDecember 2021September 2024Abandon3311NoNo
17546001COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSDecember 2021March 2026Allow5161YesNo
17613902COMPOSITION COMPRISING BIOFILM FORMING BACILLUSNovember 2021July 2025Allow4411NoNo
17607667NOVEL FAECALIBACTERIUM PRAUSNITZII STRAIN EB-FPDK11 AND USE THEREOFOctober 2021August 2025Allow4650NoNo
17513483APPLICATION OF UTX GENE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING LIPID DISEASESOctober 2021June 2024Abandon3120NoNo
17605124METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTOROctober 2021September 2025Abandon4701NoNo
17603936PRODUCTION OF SALIPRO PARTICLESOctober 2021June 2025Allow4420YesNo
17496092CHIMERIC CLOTTING FACTORSOctober 2021November 2023Abandon2501NoNo
17449173IMPLANTABLE BIOSENSOR AND METHODS OF USE THEREOFSeptember 2021October 2023Abandon2510NoNo
17459169EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEAugust 2021December 2021Allow310NoNo
17429104ENZYMATIC PRODUCTION OF MANNOSEAugust 2021February 2025Allow4220NoNo
17396028EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEAugust 2021June 2023Allow2310NoNo
17425095BETA-ARRESTIN MUTANTSJuly 2021September 2025Allow5031YesNo
17420585METHOD OF QUANTIFYING TARGET SUBSTANCE BY USING GLUCOSE METER AND CELL-FREE PROTEIN SYNTHESISJuly 2021November 2025Abandon5321NoNo
17420378ENGINEERED TRANSAMINASE POLYPEPTIDESJuly 2021August 2025Allow5031YesNo
17414245A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONSJune 2021December 2025Allow5440YesNo
17347285GENETICALLY ENCODED RATIOMETRIC FLUORESCENT BARCODESJune 2021February 2025Abandon4410NoNo
17311137PRODUCTION METHOD FOR GENOME-EDITED CELLSJune 2021November 2025Allow5431YesNo
17335357PRODUCTION OF SOLUBLE RELAXIN AND RELAXIN ANALOGSJune 2021January 2024Abandon3241NoNo
17318740DEVICE AND METHOD FOR PREPARING AND ADMINISTERING ONE-COMPONENT FIBRIN SEALANTMay 2021January 2024Allow3220NoNo
17314057RECOMBINANT PROTEINS COMPRISING BOTULINUM TOXIN AND CELL PENETRATING PEPTIDE AND COSMETIC COMPOSITION COMPRISING THEREOFMay 2021February 2024Allow3411YesNo
17244738Variants of CPF1 (CAS12a) With Altered PAM SpecificityApril 2021June 2024Allow3721YesNo
17288619COMPOSITIONS AND METHODS FOR BIODEGRADING ALCOHOLApril 2021October 2024Abandon4221NoNo
17232942METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINSApril 2021March 2024Abandon3520NoNo
17231769Stabilised Compositions of Factor VII PolypeptidesApril 2021September 2023Abandon2901NoNo
17228130HUMAN COAGULATION FACTOR VII POLYPEPTIDESApril 2021September 2023Abandon2901NoNo
17212895METHODS AND COMPOSITIONS FOR PREPARING SURFACTANT PROTEIN D (SP-D)March 2021August 2024Abandon4020NoNo
17208736THROMBOLYTIC MICROSPHERES TO DISSOLVE VASO-OCCLUSIVE CLOTSMarch 2021January 2025Abandon4621NoNo
17195615METHODS AND DEVICES FOR DETECTION OF COAGULATION IMPAIRMENTMarch 2021November 2025Abandon5621NoNo
17190994METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSIONMarch 2021August 2023Allow2910YesNo
17272803METHODS FOR IMPROVING YIELDS OF L-GLUFOSINATEMarch 2021October 2025Allow5641YesYes
17269926MICROSAMPLING DETECTION IN DIABETESFebruary 2021May 2024Abandon3811NoNo
17173289SILK FIBROIN-BASED MICRONEEDLES AND METHODS OF MAKING THE SAMEFebruary 2021September 2024Allow4320YesYes
17160814METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTSJanuary 2021September 2023Abandon3110NoNo
17155935PURIFICATION OF CHIMERIC FVIII MOLECULESJanuary 2021October 2025Allow5760YesYes
17255827COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASEDecember 2020May 2025Abandon5321NoNo
17130812DELIVERY OF NEGATIVELY CHARGED PROTEINS USING CATIONIC LIPIDSDecember 2020May 2025Abandon5321NoNo
17116817Enzyme Variants With Improved Ester Synthase PropertiesDecember 2020June 2024Abandon4220NoNo
15734682Promoter for YeastDecember 2020August 2023Allow3221YesNo
17108536MUTANT LYSENIN PORESDecember 2020August 2023Allow3211NoNo
17100806Compositions and Methods for Topical and Diagnostic and Therapeutic TransportNovember 2020July 2023Abandon3110NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TSAY, MARSHA M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
26
Examiner Affirmed
21
(80.8%)
Examiner Reversed
5
(19.2%)
Reversal Percentile
30.8%
Lower than average

What This Means

With a 19.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
156
Allowed After Appeal Filing
24
(15.4%)
Not Allowed After Appeal Filing
132
(84.6%)
Filing Benefit Percentile
18.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner TSAY, MARSHA M - Prosecution Strategy Guide

Executive Summary

Examiner TSAY, MARSHA M works in Art Unit 1656 and has examined 925 patent applications in our dataset. With an allowance rate of 46.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner TSAY, MARSHA M's allowance rate of 46.6% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by TSAY, MARSHA M receive 2.78 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TSAY, MARSHA M is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +48.2% benefit to allowance rate for applications examined by TSAY, MARSHA M. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.1% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.2% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 70.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.5% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.4% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.